What is the routine prophylaxis dosing regimen for Jivi?

For routine prophylaxis to prevent bleeding, the recommended initial dosing regimen for Jivi depends on age and is:

• 30 to 40 international units (IU) per kilogram (kg) given intravenously (IV) twice weekly for adults and children 12 years and older
• 60 IU given IV twice weekly in children aged 7 to 12 years.

Jivi (antihemophilic Factor [recombinant], PEGylated-aucl) is an injectable medicine from Bayer Health Care used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A. It is used to treat and control bleeding in previously treated adults and children 7 years of age and older.

Based on the bleeding episodes:

• The regimen may be adjusted to 45 to 60 IU/kg every 5 days in adults and children 12 years and older. In younger children it should be adjusted based on clinical response and the patient's recovery.
• Jivi can be further individually adjusted to less or more frequent dosing based on bleeding episodes.

The FDA has also approved Jivi for on-demand bleeding control and the perioperative (at or around the time of surgery) management of bleeding in the same population. See the Prescribing Information for Jivi to fully review dosing recommendations prior to use.

See also:

Drug information

• Jivi Information for Consumers
• Jivi prescribing info & package insert (for Health Professionals)
• Side Effects of Jivi (detailed)

Related support groups

• Jivi (1 questions, 4 members)
• Hemophilia A (1 questions, 5 members)

Medical Disclaimer